Opening Anti-Amyloid Monoclonal antibodies & ARIA by Dr. Rolando Cordoves-Feria, PGY4
Anti-Amyloid Monoclonal antibodies & ARIA by Dr. Rolando Cordoves-Feria, PGY4
- Length
- 1 h 9 min
- Level
- Undergraduate
- Recorded
- University of Louisville2025
Chapter 1 of 9: Before the lecture
Traces amyloid-related imaging abnormalities in Alzheimer's therapy from trial history to MRI protocols.
Anti-amyloid monoclonal antibodies and the resulting amyloid-related imaging abnormalities are examined in clinical neurology. The session traces the historical discovery of Alzheimer's disease hallmarks and the evolution of amyloid-targeting drug trials from bapineuzumab to lecanemab. Pathophysiological mechanisms link amyloid plaque clearance to transient vascular integrity loss, cortical vasogenic edema, and hemosiderin deposition. Surveillance protocols, risk factors like cerebral amyloid angiopathy, and grading criteria for both ARIA-E and ARIA-H guide patient management. Differential diagnoses and clinical symptoms such as headache and seizures establish safety protocols for continuing or halting treatment.
Anti-amyloid monoclonal antibodies and the resulting amyloid-related imaging abnormalities are examined in clinical neurology. The session traces the historical discovery of Alzheimer's disease hallmarks and the evolution of amyloid-targeting drug trials from bapineuzumab to lecanemab. Pathophysiological mechanisms link amyloid plaque clearance to transient vascular integrity loss, cortical vasogenic edema, and hemosiderin deposition. Surveillance protocols, risk factors like cerebral amyloid angiopathy, and grading criteria for both ARIA-E and ARIA-H guide patient management. Differential diagnoses and clinical symptoms such as headache and seizures establish safety protocols for continuing or halting treatment.
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients with Early Alzheimer Disease
Lecanemab in Early Alzheimer's Disease
Surveillance MRI in Patients with Alzheimer's Disease Treated with Monoclonal Antibodies: Recommendations for Detection and Grading of Amyloid-Related Imaging Abnormalities
Doctor

This lecture
Talk 28 of 115 of UofL Neurology Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in